Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CTAD 2022 | Future direction for anti-amyloid immunotherapies

Anti-amyloid immunotherapies such as aducanumab, lecanemab, and donanemab have shown promise in the treatment of early Alzheimer’s disease (AD). However, these effects remain below the established minimal clinically relevant values. Given the risk of amyloid-related imaging abnormalities (ARIA) that can, in some cases, hospitalize patients, the benefit/risk ratio of these drugs has been debated. Nicolas Villain, MD, PhD, AP-HP Sorbonne University, Pitié-Salpêtrière Hospital, Paris, France, suggests future directions for anti-amyloid immunotherapies that could help to increase their meaningful clinical benefit. These include: longer follow-ups during clinical trials, identifying individuals that respond better to the drugs, and using anti-amyloid immunotherapies in combination with other therapies. This interview took place at the Clinical Trials on Alzheimer’s Disease Congress 2022 in San Francisco.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Independent of this work, NV received research support from Fondation Bettencourt-Schueller, Fondation Servier, Union Nationale pour les Intérêts de la Médecine (UNIM), Fondation Claude Pompidou, Fondation Alzheimer and Fondation pour la Recherche sur l’Alzheimer; travel grant from the Movement Disorders Society, Merz-Pharma, UCB Pharma, and GE Healthcare SAS; is an unpaid local principal investigator or sub-investigator in NCT04241068 and NCT05310071 (aducanumab, Biogen), NCT04437511 (donanemab, Eli-Lilly), NCT05463731 (remternetug, Eli-Lilly), NCT04592341 (gantenerumab, Roche), NCT03887455 (lecanemab, Eisai), NCT03352557 (gosuranemab, Biogen), NCT03828747 and NCT03289143 (semorinemab, Roche), NCT04619420 (JNJ-63733657, Janssen – Johnson & Johnson), NCT04374136 (AL001, Alector), NCT04592874 (AL002, Alector), NCT04867616 (bepranemab, UCB Pharma), NCT04777396 and NCT04777409 (semaglutide, Novo Nordisk), is an unpaid national coordinator for NCT05564169 (masitinib, ABScience); and has given unpaid lectures in symposia organized by Eisai and the Servier Foundation.